Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISMC3 real-world pegcetacoplan study in C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis
2025-524487-37-00Phase 4Authorised
- Sponsor
- Sobi
- Start
- Jul 2026
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 4, open-label trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Primary immune complex membranoproliferative glomerulonephritis (MPGN) (2 arms), sponsored by Sobi. Primary endpoint: UPCR less than 1 g/g at 6 months. Planned start Jul 2026; status: authorised.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on 2025-524487-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524487-37-00.